{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:10:56Z","timestamp":1784308256938,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.phymed.2026.157946","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:26:09Z","timestamp":1770683169000},"page":"157946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Shexiang Baoxin pill in patients with stable coronary artery disease and reduced eGFR: Subgroup analysis of phase IV randomized trial"],"prefix":"10.1016","volume":"154","author":[{"given":"Jingmin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhe","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2026.157946_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/767424","article-title":"An update on coronary artery disease and chronic kidney disease","volume":"2014","author":"Afsar","year":"2014","journal-title":"Int. J. Nephrol."},{"issue":"1","key":"10.1016\/j.phymed.2026.157946_bib0002","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ndt\/gfae124","article-title":"Significance of eGFR and proteinuria for cardiovascular disease in individuals beyond 85 years of age","volume":"40","author":"Azegami","year":"2025","journal-title":"Nephrol. Dial. TransPlant"},{"issue":"23","key":"10.1016\/j.phymed.2026.157946_bib0003","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.phymed.2026.157946_bib0004","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phymed.2026.157946_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2023.01.008","article-title":"Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: the COMPASS trial","volume":"258","author":"Branch","year":"2023","journal-title":"Am. Heart. J."},{"issue":"6","key":"10.1016\/j.phymed.2026.157946_bib0006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/ehjcvp\/pvae030","article-title":"Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT","volume":"10","author":"Burger","year":"2024","journal-title":"Eur. Heart. J. Cardiovasc. PharmacOther"},{"issue":"8","key":"10.1016\/j.phymed.2026.157946_bib0007","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as cardiovascular risk factor in chronic kidney disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.phymed.2026.157946_bib0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1573403X10666140214122234","article-title":"Coronary artery disease in patients with chronic kidney disease: a clinical update","volume":"9","author":"Cai","year":"2013","journal-title":"Curr. Cardiol. Rev."},{"issue":"7","key":"10.1016\/j.phymed.2026.157946_bib0009","first-page":"782","article-title":"Expert consensus on shexiang baoxin pills for coronary heart disease","volume":"42","year":"2022","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.phymed.2026.157946_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fphar.2019.00052","article-title":"Cytochrome P450 3A enzymes are key contributors for hepatic metabolism of bufotalin, a natural constitute in chinese medicine chansu","volume":"10","author":"Dai","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.phymed.2026.157946_bib0011","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archinte.163.5.592","article-title":"Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients","volume":"163","author":"Davies","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.phymed.2026.157946_bib0012","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","article-title":"The effect of chronic renal failure on drug metabolism and transport","volume":"4","author":"Dreisbach","year":"2008","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phymed.2026.157946_bib0013","article-title":"A network-based method for mechanistic investigation of Shexiang Baoxin Pill's treatment of cardiovascular diseases","volume":"7","author":"Fang","year":"2017","journal-title":"Sci Rep."},{"issue":"2","key":"10.1016\/j.phymed.2026.157946_bib0014","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CM9.0000000000001257","article-title":"Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial","volume":"134","author":"Ge","year":"2021","journal-title":"Chin. Med. J. (Engl)"},{"issue":"10","key":"10.1016\/j.phymed.2026.157946_bib0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2026.157946_bib0016","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.atherosclerosis.2017.06.012","article-title":"Shexiang Baoxin pills promotes angiogenesis in myocardial infarction rats via up-regulation of 20-HETE-mediated endothelial progenitor cells mobilization","volume":"263","author":"Huang","year":"2017","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.phymed.2026.157946_bib0017","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phymed.2026.157946_bib0018","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phymed.2026.157946_bib0019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cbi.2011.12.001","article-title":"Induction of cytochrome P450 3A by Shexiang Baoxin Pill and its main components","volume":"195","author":"Jiang","year":"2012","journal-title":"Chem. Biol. Interact."},{"issue":"4S","key":"10.1016\/j.phymed.2026.157946_bib0020","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.phymed.2026.157946_bib0021","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes. Endocrinol."},{"issue":"4","key":"10.1016\/j.phymed.2026.157946_bib0022","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.phymed.2026.157946_bib0023","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phymed.2026.157946_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6710759","article-title":"Shexiang Baoxin Pill alleviates the atherosclerotic lesions in mice via improving inflammation response and inhibiting lipid accumulation in the arterial wall","volume":"2019","author":"Lu","year":"2019","journal-title":"Mediators. Inflamm."},{"issue":"10","key":"10.1016\/j.phymed.2026.157946_bib0025","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"Ma","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.phymed.2026.157946_bib0026","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure","volume":"75","author":"Marso","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phymed.2026.157946_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100020","article-title":"Drug-drug interactions in polypharmacy patients: the impact of renal impairment","volume":"2","author":"Papotti","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"5","key":"10.1016\/j.phymed.2026.157946_bib0028","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00228-022-03276-4","article-title":"Medication adherence among persons with coronary heart disease and associations with blood pressure and low-density-lipoprotein-cholesterol","volume":"78","author":"Pedersen","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"16","key":"10.1016\/j.phymed.2026.157946_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26167797","article-title":"Natural polymorphic variants in the CYP450 superfamily: a review of potential structural mechanisms and functional consequences","volume":"26","author":"Prost","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phymed.2026.157946_bib0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40620-024-01887-x","article-title":"Estimated glomerular filtration rate in observational and interventional studies in chronic kidney disease","volume":"37","author":"Provenzano","year":"2024","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.phymed.2026.157946_bib0031","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1358863X19892690","article-title":"Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2\u00b0P-TIMI 50 trial","volume":"25","author":"Qamar","year":"2020","journal-title":"Vasc. Med."},{"issue":"4","key":"10.1016\/j.phymed.2026.157946_bib0032","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcmg.2024.10.004","article-title":"Allocation of semaglutide according to coronary artery calcium and BMI: applying the SELECT trial to MESA","volume":"18","author":"Razavi","year":"2025","journal-title":"JACC. Cardiovasc. ImAging"},{"issue":"7","key":"10.1016\/j.phymed.2026.157946_bib0033","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.105.003822","article-title":"CYP3A5 genetic polymorphisms in different ethnic populations","volume":"33","author":"Roy","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"14","key":"10.1016\/j.phymed.2026.157946_bib0034","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.phymed.2026.157946_bib0035","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.phymed.2026.157946_bib0036","first-page":"5545","article-title":"Potential herb-drug interaction of shexiang baoxin pill in vitro based on drug metabolism\/transporter","volume":"8","author":"Shen","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"5","key":"10.1016\/j.phymed.2026.157946_bib0037","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1021\/acs.jmedchem.1c01875","article-title":"Unique oxidative metabolism of bufalin generates two reactive metabolites that strongly inactivate human cytochrome P450 3A","volume":"65","author":"Tu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.phymed.2026.157946_bib0038","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc7093","article-title":"Clinical review: drug metabolism and nonrenal clearance in acute kidney injury","volume":"12","author":"Vilay","year":"2008","journal-title":"Crit. Care"},{"issue":"1","key":"10.1016\/j.phymed.2026.157946_bib0039","article-title":"Trends of cause-specific cardiovascular disease mortality in China, 2009-2019: a nationwide longitudinal study","volume":"57","author":"Wang","year":"2025","journal-title":"Ann. Med."},{"issue":"5","key":"10.1016\/j.phymed.2026.157946_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/heartjnl-2024-324650","article-title":"Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort","volume":"111","author":"Wang","year":"2025","journal-title":"Heart."},{"key":"10.1016\/j.phymed.2026.157946_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1002713","article-title":"Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: a systematic review and meta-analysis of 42 randomized controlled trials","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"51","key":"10.1016\/j.phymed.2026.157946_bib0042","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013580","article-title":"Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: a systematic review and meta-analysis","volume":"97","author":"Wen","year":"2018","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.phymed.2026.157946_bib0043","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijcard.2012.10.048","article-title":"Drug adherence and the incidence of coronary heart disease- and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: a five-year cohort study","volume":"168","author":"Wong","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"10166","key":"10.1016\/j.phymed.2026.157946_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2026.157946_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2019.11.005","article-title":"Mechanism of angiogenesis promotion with Shexiang Baoxin Pills by regulating function and signaling pathway of endothelial cells through macrophages","volume":"292","author":"Zhang","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phymed.2026.157946_bib0046","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.18636","article-title":"CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ."},{"issue":"1","key":"10.1016\/j.phymed.2026.157946_bib0047","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11655-019-3162-z","article-title":"Effect of Shexiang Baoxin Pill in alleviating early hypertensive renal injury in rats","volume":"27","author":"Zhao","year":"2021","journal-title":"Chin. J. Integr. Med."},{"issue":"1","key":"10.1016\/j.phymed.2026.157946_bib0048","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/CM9.0000000000002527","article-title":"Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial","volume":"136","author":"Zhou","year":"2023","journal-title":"Chin. Med. J. (Engl)"},{"issue":"11","key":"10.1016\/j.phymed.2026.157946_bib0049","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the european renal and cardiovascular medicine working group of the European renal association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc. Res."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326001844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326001844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:42:53Z","timestamp":1774010573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711326001844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"alternative-id":["S0944711326001844"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2026.157946","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shexiang Baoxin pill in patients with stable coronary artery disease and reduced eGFR: Subgroup analysis of phase IV randomized trial","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2026.157946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"157946"}}